Orexigen Therapeutics (OREX) Tops Q3 EPS by 7c, Revenue Misses

November 5, 2015 4:07 PM EST

Orexigen Therapeutics (NASDAQ: OREX) reported Q3 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $10 million versus the consensus estimate of $12.17 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings